StreetInsider.com News Articles

Amgen (AMGN) PT Raised to $435 at Wells Fargo

Fri, 04 Sep 2026 05:27:03 -0400

Wells Fargo analyst Mohit Bansal raised the price target on Amgen (NASDAQ: AMGN) to $435.00 (from $400.00) while maintaining a Equal Weight rating.

The analyst comments "A positive pelacarsen outcome would likely be one of the most important de-risking events for olpasiran to date. Conversely, a negative readout would raise questions for the Lp(a) class. That said, the initial press release for HORIZON is likely to provide limited details and note only whether the trial is positive or negative. Assuming a positive trial, we could see an increase in POS to 70% adding $10-15/sh while a negative trial could erase $20-25/sh

Amgen (AMGN) PT Raised to $435 at Wells Fargo

Fri, 04 Sep 2026 05:27:03 -0400

Wells Fargo analyst Mohit Bansal raised the price target on Amgen (NASDAQ: AMGN) to $435.00 (from $400.00) while maintaining a Equal Weight rating.

Amgen (AMGN) call put ratio 1 call to 1.1 puts

Mon, 31 Aug 2026 05:47:29 -0400

Amgen (NASDAQ: AMGN) 30-day call option implied volatility is 34; compared to its 52-week range of 21 to 37. Call put ratio 1 call to 1.1 puts.

Amgen's Tezspire meets all endpoints in phase 3 esophagitis trial

Thu, 27 Aug 2026 02:00:31 -0400

Amgen (NASDAQ: AMGN) and AstraZeneca announced positive top-line results from the phase 3 CROSSING trial of Tezspire (tezepelumab-ekko) in patients with eosinophilic esophagitis, a chronic inflammatory disorder of the esophagus.

The trial met both co-primary endpoints at week 24: histologic remission, defined as a peak esophageal eosinophil count of six or fewer eosinophils per high-power field, and mean change from baseline in the Dysphagia Symptom Questionnaire score, which measures the frequency and severity of difficulty swallowing. Improvements were sustained through week 52, and all key secondary endpoints were also met. The drug's safety profile was described as generally consistent with its

Amgen's Tezspire meets all endpoints in phase 3 esophagitis trial

Thu, 27 Aug 2026 02:00:31 -0400

TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS

Thu, 27 Aug 2026 02:00:00 -0400

Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52

Efficacy in a Third Epithelial-Driven Inflammatory Disease Supports Broad Potential of TEZSPIRE

THOUSAND OAKS, Calif., Aug. 27, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 CROSSING trial of TEZSPIRE^® (tezepelumab-ekko) in patients living with eosinophilic esophagitis (EoE). TEZSPIRE demonstrated statistically significant and clinically meaningful improvements across co-primary and key secondary endpoints at week 24 which were sustained through week 52. The co-primary endpoints were histologic remission and the frequency

TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS

Thu, 27 Aug 2026 02:00:00 -0400

Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52

Efficacy in a Third Epithelial-Driven Inflammatory Disease Supports Broad Potential of TEZSPIRE

TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS

Thu, 27 Aug 2026 02:00:00 -0400

Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52

Efficacy in a Third Epithelial-Driven Inflammatory Disease Supports Broad Potential of TEZSPIRE

TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS

Thu, 27 Aug 2026 02:00:00 -0400

Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52

Efficacy in a Third Epithelial-Driven Inflammatory Disease Supports Broad Potential of TEZSPIRE

FTC files amicus brief challenging Amgen's Enbrel patent acquisition

Fri, 21 Aug 2026 11:58:57 -0400

(Updated - August 21, 2026 11:58 AM EDT)

The Federal Trade Commission filed an amicus brief in the U.S. Court of Appeals for the Fourth Circuit, arguing that Amgen's acquisition of patent applications related to its biologic drug Enbrel is subject to antitrust scrutiny.

The FTC stated the brief was filed to protect competition in biologic drug markets. CareFirst of Maryland and its affiliates allege that Amgen's acquisition violated Section 2 of the Sherman Act, accusing the company of obtaining exclusive rights to patent applications and then using those applications to extend its monopoly over Enbrel while blocking lower-cost competitors.

Amgen argued its

Amgen (AMGN) PT Raised to $457 at Piper Sandler

Thu, 20 Aug 2026 07:22:41 -0400

Piper Sandler analyst David Amsellem raised the price target on Amgen (NASDAQ: AMGN) to $457.00 (from $427.00) while maintaining a Overweight rating.

Amgen (AMGN) PT Raised to $362 at Morgan Stanley

Wed, 19 Aug 2026 09:07:50 -0400

Morgan Stanley analyst Terance Flynn raised the price target on Amgen (NASDAQ: AMGN) to $362.00 (from $351.00) while maintaining a Equalweight rating.

Amgen (AMGN) PT Raised to $460 at Argus

Wed, 19 Aug 2026 07:24:47 -0400

Argus analyst David Toung raised the price target on Amgen (NASDAQ: AMGN) to $460.00 while maintaining a Buy rating.

Amgen (AMGN) PT Raised to $400 at Cantor Fitzgerald on Higher Sales Estimates

Tue, 18 Aug 2026 08:59:17 -0400

(Updated - August 18, 2026 8:59 AM EDT)

Cantor Fitzgerald analyst Carter Gould raised the price target on Amgen (NASDAQ: AMGN) to $400.00 (from $350.00) while maintaining a Neutral rating.

The analyst commented, "On the back of the core portfolio drivers (most notably Repatha, Evenity, Uplizna), we have raised our FY26 top-line forecast to $39.2bn (still $400mn above the top end of the guide)...We update our model to reflect 2Q results and recent trends. Our PT raise is primarily driven by higher sales estimates going forward, reflecting a better outlook for core portfolio drivers. The net impact of our model changes is

Amgen (AMGN) PT Raised to $400 at Cantor Fitzgerald on Higher Sales Estimates

Tue, 18 Aug 2026 08:59:17 -0400

(Updated - August 18, 2026 8:59 AM EDT)

Cantor Fitzgerald analyst Carter Gould raised the price target on Amgen (NASDAQ: AMGN) to $400.00 (from $350.00) while maintaining a Neutral rating.

Amgen (AMGN) PT Raised to $352 at Mizuho

Tue, 18 Aug 2026 06:36:12 -0400

Mizuho analyst Salim Syed raised the price target on Amgen (NASDAQ: AMGN) to $352.00 (from $303.00) while maintaining a Neutral rating.

Amgen (AMGN) PT Raised to $380 at Barclays

Fri, 14 Aug 2026 04:20:49 -0400

Barclays analyst Carter Gould raised the price target on Amgen (NASDAQ: AMGN) to $380.00 (from $360.00) while maintaining a Equalweight rating.

Form 4 AMGEN INC For: Aug 11 Filed by: Khosla Rachna

Thu, 13 Aug 2026 19:06:00 -0400

si-local-file:///var/storage/secattach/20260813/26923117.html

Form 4 AMGEN INC For: Aug 11 Filed by: Khosla Rachna

Thu, 13 Aug 2026 19:06:00 -0400

si-local-file:///var/storage/secattach/20260813/26923117.html

Form 144 AMGEN INC Filed by: Khosla Rachna

Thu, 13 Aug 2026 11:14:00 -0400

si-local-file:///var/storage/secattach/20260813/26918530.html

Form 144 AMGEN INC Filed by: Khosla Rachna

Thu, 13 Aug 2026 11:14:00 -0400

si-local-file:///var/storage/secattach/20260813/26918530.html

Form 4 AMGEN INC For: Aug 07 Filed by: Busch Matthew C.

Wed, 12 Aug 2026 20:05:00 -0400

si-local-file:///var/storage/secattach/20260812/26914847.html

Form 4 AMGEN INC For: Aug 07 Filed by: Busch Matthew C.

Wed, 12 Aug 2026 20:05:00 -0400

si-local-file:///var/storage/secattach/20260812/26914847.html

Form 144 AMGEN INC Filed by: Khosla Rachna

Tue, 11 Aug 2026 15:41:00 -0400

si-local-file:///var/storage/secattach/20260811/26905265.html

Form 144 AMGEN INC Filed by: Khosla Rachna

Tue, 11 Aug 2026 15:41:00 -0400

si-local-file:///var/storage/secattach/20260811/26905265.html